trending Market Intelligence /marketintelligence/en/news-insights/trending/mqOmOAOWISvOEEC1EOzbvw2 content esgSubNav
In This List

NICE rejects Bayer's liver cancer drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


NICE rejects Bayer's liver cancer drug

The U.K.'s National Institute for Health and Care Excellence rejected another oncology drug, this time Bayer AG's Sorafenib for use in patients with liver cancer.

The government body, which evaluates drugs for use in the National Health Service, said the drug did not provide enough benefit to justify its high cost.

NICE, however, said that Sorafenib should continue to be recommended for use within the Cancer Drugs Fund.

NICE's recommendation against the use of the drug under the NHS is preliminary and the government body is open to consultation. NICE also recently rejected Roche Holding Ltd.'s breast cancer drug Kadcyla on financial grounds.